SCHEMBL25890753

SCHEMBL25890753

O=C(O)CN1CCN(CC(=O)O)CCN(CC(=O)CN2C(=O)CCC2=O)CCN(CC(=O)O)CC1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.41
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TSHR P16473 2/20 0.39
SLC6A9 P48067 1/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
GSK3A P49840 1/20 0.36
GSK3B P49841 1/20 0.36
ALDH1A1 P00352 3/20 0.35
ALOX12 P18054 1/20 0.35
CHRM2 P08172 1/20 0.34
CHRM4 P08173 1/20 0.34
CHRM5 P08912 1/20 0.34
CHRM1 P11229 1/20 0.34
CHRM3 P20309 1/20 0.34
GAA P10253 1/20 0.33
LMNA P02545 1/20 0.33
S1PR1 P21453 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25499543 0.85 HSD17B10 (0.32) HSD17B10RAB9ASMN1; SMN2TSHRSLC6A9
SCHEMBL236431 0.80 TSHR (0.56) RAB9ASMN1; SMN2TSHRMEN1KMT2A
SCHEMBL4524807 0.79 MAPT (0.57) SMN1; SMN2MEN1KMT2AALDH1A1CHRM2
Tetraxetan SCHEMBL1009948 0.79 HSD17B10 (0.45) HSD17B10TSHRSLC6A9MEN1KMT2A
SCHEMBL24465093 0.78
SCHEMBL24465087 0.76 PKM (0.38) MEN1KMT2AALDH1A1CHRM2CHRM4
SCHEMBL31240941 0.76 HSD17B10 (0.42) HSD17B10SMN1; SMN2TSHRSLC6A9KMT2A
SCHEMBL1269478 0.75 RAB9A (0.42) RAB9ASMN1; SMN2TSHRMEN1KMT2A
SCHEMBL6848102 0.74 HSD17B10 (0.64) HSD17B10SMN1; SMN2TSHRSLC6A9ALDH1A1
Tetraxetan SCHEMBL2635294 0.74 HSD17B10 (0.64) HSD17B10SMN1; SMN2TSHRSLC6A9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230330275-A1 FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO TRUSTEES OF TUFTS COLLEGE 2023-10-19 US disclosed
US-11707539-B2 FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto TRUSTEES OF TUFTS COLLEGE (US) 2023-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230330275-A1 FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO FAP, APC, FIBP HSD17B10 3607/4885RAB9A 1421/4885SMN1; SMN2 1350/4885
US-11707539-B2 FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto FAP, APC, FIBP HSD17B10 3607/4885RAB9A 1421/4885SMN1; SMN2 1350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.